Symbols / SLS
SLS Chart
About
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 770.27M |
| Enterprise Value | 631.46M | Income | -25.94M | Sales | — |
| Book/sh | 0.36 | Cash/sh | 0.31 | Dividend Yield | — |
| Payout | 0.00% | Employees | 15 | IPO | — |
| P/E | — | Forward P/E | -14.28 | PEG | — |
| P/S | — | P/B | 12.39 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 7.48 |
| Current Ratio | 8.28 | Debt/Eq | 1.31 | LT Debt/Eq | — |
| EPS (ttm) | -0.28 | EPS next Y | -0.32 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-19 | ROA | -44.90% |
| ROE | -84.33% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 170.28M |
| Shs Float | 141.79M | Short Float | 24.42% | Short Ratio | 3.28 |
| Short Interest | — | 52W High | 5.18 | 52W Low | 0.95 |
| Beta | 2.25 | Avg Volume | 8.35M | Volume | 3.64M |
| Target Price | $6.83 | Recom | None | Prev Close | $4.74 |
| Price | $4.52 | Change | -4.57% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.83
Mean price target
2. Current target
$4.55
Latest analyst target
3. DCF / Fair value
$-2.33
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.55
Low
$6.00
High
$7.50
Mean
$6.83
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-07-16 | main | Maxim Group | Buy → Buy | $7 |
| 2023-11-22 | reit | Cantor Fitzgerald | Overweight → Overweight | $3 |
| 2023-09-07 | reit | Cantor Fitzgerald | Overweight → Overweight | $3 |
| 2022-11-15 | main | Alliance Global Partners | — → Buy | $8 |
| 2022-06-28 | main | Cantor Fitzgerald | — → Overweight | $6 |
| 2021-07-21 | init | Cantor Fitzgerald | — → Overweight | $18 |
| 2019-11-15 | up | Maxim Group | Hold → Buy | $12 |
| 2019-04-08 | init | Alliance Global Partners | — → Buy | $5 |
| 2018-11-01 | init | Oppenheimer | — → Outperform | $13 |
| 2018-07-20 | main | Maxim Group | Buy → Buy | $5 |
| 2018-04-02 | init | HC Wainwright & Co. | — → Buy | $11 |
| 2018-03-19 | up | Maxim Group | Hold → Buy | — |
News
RSS: Latest SLS news- Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% - Stocktwits Mon, 23 Feb 2026 18
- (SLS) Advanced Trading Insights (SLS:CA) - Stock Traders Daily ue, 24 Feb 2026 09
- $SLS stock is up 3% today. Here's what we see in our data. - Quiver Quantitative Wed, 18 Feb 2026 19
- A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Collaboration - simplywall.st hu, 15 Jan 2026 08
- BA Stock Today: February 23 — Artemis II Rollback Puts SLS on Watch - Meyka Mon, 23 Feb 2026 00
- Why SLS stock is jumping premarket: SELLAS Life Sciences puts REGAL Phase 3 countdown back in play - Bez Kabli Mon, 23 Feb 2026 11
- Why I’m Selling Sellas Life Sciences Ahead Of The REGAL Reveal (NASDAQ:SLS) - Seeking Alpha Mon, 19 Jan 2026 08
- Leukemia study awaits 80th death to trigger final analysis - Stock Titan Mon, 29 Dec 2025 08
- $SLS stock is down 5% today. Here's what we see in our data. - Quiver Quantitative hu, 05 Feb 2026 08
- BA Stock Today: February 22 – Artemis II Delay Puts SLS Rollback in Play - Meyka Sun, 22 Feb 2026 22
- SLS Stock Breaches $5 Level After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B - Stocktwits ue, 06 Jan 2026 00
- Why Is SLS Stock Drawing Significant Investor Attention Today? - Stocktwits Wed, 31 Dec 2025 08
- SELLAS Life Sciences Group Stock (SLS) Opinions on Phase 3 Trial Progress - Quiver Quantitative Fri, 02 Jan 2026 08
- SLS Stock Has Risen 78% In A Month — What’s The Retail Buzz About? - Stocktwits Wed, 24 Dec 2025 08
- Assessing SELLAS Life Sciences Group (SLS) Valuation After Positive Leukemia Data and Supportive FDA Designations - Yahoo Finance hu, 25 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 50000 | — | — | Stock Award(Grant) at price 0.00 per share. | SCHEINBERG DAVID A | Director | — | 2026-01-07 00:00:00 | D |
| 1 | 50000 | — | — | Stock Award(Grant) at price 0.00 per share. | WASMAN JANE | Director | — | 2026-01-07 00:00:00 | D |
| 2 | 300000 | — | — | Stock Award(Grant) at price 0.00 per share. | CICIC DRAGAN | Officer | — | 2026-01-07 00:00:00 | D |
| 3 | 300000 | — | — | Stock Award(Grant) at price 0.00 per share. | BURNS JOHN THOMAS | Chief Financial Officer | — | 2026-01-07 00:00:00 | D |
| 4 | 50000 | — | — | Stock Award(Grant) at price 0.00 per share. | KALIN KATHERINE BACH | Director | — | 2026-01-07 00:00:00 | D |
| 5 | 50000 | — | — | Stock Award(Grant) at price 0.00 per share. | VARIAN JOHN W | Director | — | 2026-01-07 00:00:00 | D |
| 6 | 50000 | — | — | Stock Award(Grant) at price 0.00 per share. | VAN NOSTRAND ROBERT L | Director | — | 2026-01-07 00:00:00 | D |
| 7 | 63400 | 100806 | — | Purchase at price 1.59 per share. | KALIN KATHERINE BACH | Director | — | 2025-11-19 00:00:00 | D |
| 8 | 10000 | 14800 | — | Purchase at price 1.48 per share. | VAN NOSTRAND ROBERT L | Director | — | 2025-06-12 00:00:00 | D |
| 9 | 20000 | 33800 | — | Purchase at price 1.69 per share. | WASMAN JANE | Director | — | 2025-05-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | -15.26K |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.01 |
| NormalizedEBITDA | -31.51M | -37.87M | -22.28M | -18.25M |
| TotalUnusualItems | 4.00K | -9.67M | -1.35M | |
| TotalUnusualItemsExcludingGoodwill | 4.00K | -9.67M | -1.35M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -30.88M | -37.34M | -41.30M | -20.70M |
| ReconciledCostOfRevenue | 0.00 | 100.00K | 200.00K | |
| EBITDA | -31.51M | -37.87M | -31.95M | -19.59M |
| EBIT | -31.51M | -37.87M | -31.95M | -19.59M |
| NetInterestIncome | 632.00K | 525.00K | 317.00K | 6.00K |
| InterestIncome | 632.00K | 525.00K | 317.00K | 6.00K |
| NormalizedIncome | -30.88M | -37.34M | -31.63M | -19.37M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -30.88M | -37.34M | -41.30M | -20.70M |
| TotalExpenses | 31.51M | 37.87M | 32.95M | 27.19M |
| TotalOperatingIncomeAsReported | -31.51M | -37.87M | -41.95M | -25.29M |
| DilutedAverageShares | 61.20M | 27.78M | 19.40M | 15.48M |
| BasicAverageShares | 61.20M | 27.78M | 19.40M | 15.48M |
| DilutedEPS | -0.50 | -1.34 | -2.13 | -1.34 |
| BasicEPS | -0.50 | -1.34 | -2.13 | -1.34 |
| DilutedNIAvailtoComStockholders | -30.88M | -37.34M | -41.30M | -20.70M |
| NetIncomeCommonStockholders | -30.88M | -37.34M | -41.30M | -20.70M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -30.88M | -37.34M | -41.30M | -20.70M |
| NetIncomeIncludingNoncontrollingInterests | -30.88M | -37.34M | -41.30M | -20.70M |
| NetIncomeContinuousOperations | -30.88M | -37.34M | -41.30M | -20.70M |
| TaxProvision | 0.00 | -237.00K | ||
| PretaxIncome | -30.88M | -37.34M | -41.30M | -20.94M |
| OtherIncomeExpense | 4.00K | -9.67M | -1.35M | |
| SpecialIncomeCharges | 0.00 | -9.70M | -1.36M | |
| OtherSpecialCharges | 10.00M | |||
| ImpairmentOfCapitalAssets | 0.00 | 5.70M | ||
| RestructuringAndMergernAcquisition | 0.00 | -296.00K | -4.34M | |
| GainOnSaleOfSecurity | 4.00K | 36.00K | 15.00K | |
| NetNonOperatingInterestIncomeExpense | 632.00K | 525.00K | 317.00K | 6.00K |
| InterestIncomeNonOperating | 632.00K | 525.00K | 317.00K | 6.00K |
| OperatingIncome | -31.51M | -37.87M | -31.95M | -19.59M |
| OperatingExpense | 31.51M | 37.87M | 32.85M | 26.99M |
| ResearchAndDevelopment | 19.10M | 24.01M | 20.27M | 15.67M |
| SellingGeneralAndAdministration | 12.42M | 13.86M | 12.58M | 11.32M |
| GeneralAndAdministrativeExpense | 12.42M | 13.86M | 12.58M | 11.32M |
| OtherGandA | 12.42M | 13.86M | 12.58M | 11.32M |
| GrossProfit | 0.00 | 900.00K | 7.40M | |
| CostOfRevenue | 0.00 | 100.00K | 200.00K | |
| TotalRevenue | 0.00 | 0.00 | 1.00M | 7.60M |
| OperatingRevenue | 0.00 | 0.00 | 1.00M | 7.60M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 73.98M | 32.13M | 21.01M | 15.90M |
| ShareIssued | 73.98M | 32.13M | 21.01M | 15.90M |
| TotalDebt | 1.00M | 906.00K | 945.00K | 808.00K |
| TangibleBookValue | 7.55M | -9.89M | 2.94M | 18.43M |
| InvestedCapital | 9.46M | -7.98M | 4.85M | 20.35M |
| WorkingCapital | 6.82M | -10.56M | 2.24M | 18.06M |
| NetTangibleAssets | 7.55M | -9.89M | 2.94M | 18.43M |
| CapitalLeaseObligations | 1.00M | 906.00K | 945.00K | 808.00K |
| CommonStockEquity | 9.46M | -7.98M | 4.85M | 20.35M |
| TotalCapitalization | 9.46M | -7.98M | 4.85M | 20.35M |
| TotalEquityGrossMinorityInterest | 9.46M | -7.98M | 4.85M | 20.35M |
| StockholdersEquity | 9.46M | -7.98M | 4.85M | 20.35M |
| RetainedEarnings | -248.12M | -217.24M | -179.90M | -138.60M |
| AdditionalPaidInCapital | 257.58M | 209.26M | 184.75M | 158.95M |
| CapitalStock | 7.00K | 3.00K | 2.00K | 2.00K |
| CommonStock | 7.00K | 3.00K | 2.00K | 2.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 9.97M | 14.20M | 16.09M | 5.93M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 457.00K | 460.00K | 577.00K | 946.00K |
| OtherNonCurrentLiabilities | 296.00K | |||
| DerivativeProductLiabilities | 0.00 | 4.00K | 40.00K | |
| NonCurrentDeferredLiabilities | 0.00 | |||
| NonCurrentDeferredTaxesLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 457.00K | 460.00K | 573.00K | 610.00K |
| LongTermCapitalLeaseObligation | 457.00K | 460.00K | 573.00K | 610.00K |
| CurrentLiabilities | 9.51M | 13.73M | 15.52M | 4.98M |
| OtherCurrentLiabilities | 42.00K | 42.00K | 161.00K | |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 544.00K | 446.00K | 372.00K | 198.00K |
| CurrentCapitalLeaseObligation | 544.00K | 446.00K | 372.00K | 198.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.78M | 1.49M | 1.44M | 989.00K |
| PayablesAndAccruedExpenses | 7.15M | 11.75M | 13.70M | 3.63M |
| CurrentAccruedExpenses | 3.65M | 6.12M | 4.85M | 1.49M |
| Payables | 3.50M | 5.64M | 8.86M | 2.14M |
| OtherPayable | 5.50M | |||
| AccountsPayable | 3.50M | 5.64M | 3.36M | 2.14M |
| TotalAssets | 19.43M | 6.22M | 20.94M | 26.27M |
| TotalNonCurrentAssets | 3.10M | 3.05M | 3.19M | 3.23M |
| OtherNonCurrentAssets | 266.00K | 275.00K | 399.00K | 594.00K |
| NonCurrentPrepaidAssets | 399.00K | 594.00K | ||
| GoodwillAndOtherIntangibleAssets | 1.91M | 1.91M | 1.91M | 1.91M |
| Goodwill | 1.91M | 1.91M | 1.91M | 1.91M |
| NetPPE | 925.00K | 858.00K | 874.00K | 723.00K |
| GrossPPE | 925.00K | 858.00K | 874.00K | 723.00K |
| OtherProperties | 925.00K | 858.00K | 874.00K | 723.00K |
| CurrentAssets | 16.33M | 3.17M | 17.76M | 23.04M |
| OtherCurrentAssets | 46.00K | 27.00K | ||
| RestrictedCash | 100.00K | 100.00K | 100.00K | 100.00K |
| PrepaidAssets | 2.34M | 542.00K | 485.00K | 1.56M |
| Receivables | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 13.89M | 2.53M | 17.12M | 21.36M |
| CashAndCashEquivalents | 13.89M | 2.53M | 17.12M | 21.36M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -35.40M | -36.91M | -28.31M | -26.02M |
| IssuanceOfCapitalStock | 46.16M | 22.23M | 23.99M | 9.01M |
| CapitalExpenditure | -5.50M | -4.50M | ||
| EndCashPosition | 13.99M | 2.63M | 17.23M | 21.45M |
| BeginningCashPosition | 2.63M | 17.23M | 21.45M | 35.40M |
| ChangesInCash | 11.36M | -14.60M | -4.23M | -13.95M |
| FinancingCashFlow | 46.76M | 22.32M | 24.08M | 12.07M |
| CashFlowFromContinuingFinancingActivities | 46.76M | 22.32M | 24.08M | 12.07M |
| NetOtherFinancingCharges | -64.00K | -31.00K | ||
| ProceedsFromStockOptionExercised | 658.00K | 121.00K | 85.00K | 3.07M |
| NetCommonStockIssuance | 46.16M | 22.23M | 23.99M | 9.01M |
| CommonStockIssuance | 46.16M | 22.23M | 23.99M | 9.01M |
| InvestingCashFlow | 0.00 | -5.50M | -4.50M | 0.00 |
| CashFlowFromContinuingInvestingActivities | 0.00 | -5.50M | -4.50M | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | -5.50M | -4.50M | 0.00 |
| PurchaseOfIntangibles | 0.00 | -5.50M | -4.50M | 0.00 |
| OperatingCashFlow | -35.40M | -31.41M | -23.81M | -26.02M |
| CashFlowFromContinuingOperatingActivities | -35.40M | -31.41M | -23.81M | -26.02M |
| ChangeInWorkingCapital | -6.65M | 3.35M | 5.64M | -7.62M |
| ChangeInOtherWorkingCapital | -5.60M | |||
| ChangeInOtherCurrentLiabilities | -533.00K | -518.00K | -471.00K | -183.00K |
| ChangeInPayablesAndAccruedExpense | -4.32M | 3.75M | 4.86M | -1.79M |
| ChangeInAccruedExpense | -2.18M | 1.45M | 3.65M | 727.00K |
| ChangeInPayable | -2.14M | 2.30M | 1.21M | -2.51M |
| ChangeInAccountPayable | -2.14M | 2.30M | 1.21M | -2.51M |
| ChangeInPrepaidAssets | -1.79M | 113.00K | 1.25M | -1.17M |
| ChangeInReceivables | 0.00 | 1.13M | ||
| OtherNonCashItems | 561.00K | 495.00K | 10.16M | -4.16M |
| StockBasedCompensation | 1.56M | 2.09M | 1.73M | 1.01M |
| AssetImpairmentCharge | 0.00 | 5.70M | ||
| DeferredTax | 0.00 | -239.00K | ||
| DeferredIncomeTax | 0.00 | -239.00K | ||
| OperatingGainsLosses | -4.00K | -36.00K | -15.00K | |
| GainLossOnInvestmentSecurities | -4.00K | -36.00K | -15.00K | |
| NetIncomeFromContinuingOperations | -30.88M | -37.34M | -41.30M | -20.70M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SLS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|